Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
0.0066
-0.0023 (-25.84%)
At close: May 16, 2025, 4:00 PM
0.0083
+0.0017 (25.76%)
After-hours: May 16, 2025, 7:59 PM EDT
Polyrizon Employees
As of December 31, 2024, Polyrizon had 6 total employees, including 2 full-time and 4 part-time employees.
Employees
6
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$267,500
Market Cap
44.91K
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
PLRZ News
- 4 days ago - Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment - GlobeNewsWire
- 22 days ago - Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model - GlobeNewsWire
- 5 weeks ago - Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements - GlobeNewsWire
- 6 weeks ago - Polyrizon Engages Leading Branding Firm for Strategic Brand Development - GlobeNewsWire
- 6 weeks ago - Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement - GlobeNewsWire
- 6 weeks ago - Polyrizon Ltd. Announces $17.0 Million Private Placement - GlobeNewsWire
- 7 weeks ago - Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting - GlobeNewsWire
- 7 weeks ago - Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment - GlobeNewsWire